Table 1 Characteristics of participants stratified by cSBP groups
Characteristics | Total | cSBP groups (mmHg) | p value | ||
---|---|---|---|---|---|
<120 | 120–140 | ≥140 | |||
n | 953 | 222 | 427 | 304 | |
Malea | 349 (36.62%) | 75 (33.78%) | 160 (37.47%) | 114 (37.50%) | 0.605 |
Age (year)b | 52.11 ± 4.74 | 50.55 ± 4.99 | 52.09 ± 4.55 | 53.29 ± 4.49 | <0.001 |
BMI (kg/m2)b | 25.84 ± 3.27 | 25.23 ± 3.50 | 25.77 ± 3.22 | 26.38 ± 3.07 | <0.001 |
Scr (μmol/l)b | 65.23 ± 13.88 | 65.10 ± 13.70 | 65.26 ± 13.64 | 65.28 ± 14.39 | 0.987 |
cSBP (mmHg)b | 132.55 ± 18.18 | 110.72 ± 8.27 | 129.11 ± 5.50 | 153.33 ± 12.11 | <0.001 |
pSBP (mmHg)b | 130.76 ± 15.40 | 119.84 ± 12.63 | 128.21 ± 11.90 | 142.31 ± 14.11 | <0.001 |
Baseline max cIMT (μm)b | 813.52 ± 118.49 | 780.41 ± 108.71 | 804.00 ± 111.95 | 851.05 ± 124.61 | <0.001 |
Baseline mean cIMT (μm)b | 681.11 ± 99.90 | 656.76 ± 90.03 | 672.97 ± 94.23 | 710.33 ± 107.59 | <0.001 |
Follow-up max cIMT (μm)b | 884.09 ± 128.39 | 844.71 ± 122.29 | 879.64 ± 123.86 | 919.10 ± 130.08 | <0.001 |
Follow-up mean cIMT (μm)b | 698.87 ± 96.58 | 671.71 ± 94.13 | 692.47 ± 91.52 | 727.68 ± 98.15 | <0.001 |
Current smokinga | 211 (22.14%) | 55 (24.77%) | 95 (22.25%) | 61 (20.07%) | 0.437 |
History of disease | |||||
Hypertensiona | 388 (40.71%) | 43 (19.37%) | 129 (30.21%) | 216 (71.05%) | <0.001 |
Diabetesa | 172 (18.05%) | 34 (15.32%) | 66 (15.46%) | 72 (23.68%) | 0.008 |
Dyslipidemiaa | 671 (70.41%) | 138 (62.16%) | 300 (70.26%) | 233 (76.64%) | 0.002 |
Medication use | |||||
Antihypertensivea | 228 (24.05%) | 31 (14.03%) | 71 (16.75%) | 126 (41.58%) | <0.001 |
Lipid-loweringa | 79 (8.36%) | 15 (6.82%) | 33 (7.80%) | 31 (10.26%) | 0.319 |
Antidiabetesa | 74 (7.79%) | 15 (6.79%) | 26 (6.12%) | 33 (10.86%) | 0.051 |